Skip to main content
Premium Trial:

Request an Annual Quote

454 Extends License to Biotage Sequencing Technology

NEW YORK, Sept. 17 (GenomeWeb News) - 454 has extended a one-year license to now include exclusive rights to synthesizing technologies owned by Biotage, the company said today.

New Haven, Conn.-based 454 has obtains the rights to sequencing by synthesis and pyrophosphate-based sequencing for whole genome and other high density and high-throughput applications.

 

The company's minimum royalty payment of $1 million annually will increase to $1.25 million a year for two years, and 454 has the right to continue the agreement throughout the lifetime of the patents. 454 has already paid $3 million toward an estimated minimum of $13 million through 2014, Stockholm, Sweden-based Biotage said.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.